CEREVEL THERAPEUTICS HOLDINGS, INC.
222 Jacobs Street, Suite 200
Cambridge, MA 02141
VIA EDGAR
June 29, 2021
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Irene Paik
| Re: | Cerevel Therapeutics Holdings, Inc. | |||
| Acceleration Request for Registration Statement on Form S-1 | ||||
| Filed June 29, 2021 | ||||
| File No. 333-257505 | ||||
| Acceleration Request | ||||
| Requested Date: | July 1, 2021 | |||
| Requested Time: | 4:01 p.m., Eastern Time | |||
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Cerevel Therapeutics Holdings, Inc. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 1, 2021, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Nicole Daley at (617) 570-1354. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective date and time of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Nicole Daley, by email to NDaley@goodwinlaw.com or by facsimile to (617) 830-0982.
If you have any questions regarding this request, please contact Nicole Daley of Goodwin Procter LLP at (617) 570-1354.
| Sincerely, |
| CEREVEL THERAPEUTICS HOLDINGS, INC. |
/s/ N. Anthony Coles |
| N. Anthony Coles |
| Chief Executive Officer |
| cc: | Kathy Yi, Cerevel Therapeutics Holdings, Inc. |
Scott Akamine, Cerevel Therapeutics Holdings, Inc.
Stuart M. Cable, Goodwin Procter LLP
Arthur R. McGivern, Goodwin Procter LLP
